Announcement • Dec 04
TC Biopharm (Holdings) Files Form 15 TC Biopharm (Holdings) Plc has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its American Depositary Shares, each representing four thousand Ordinary shares, nominal value of £0.000001 per Ordinary share under the Securities Exchange Act of 1934, as amended. Announcement • Aug 07
TC Biopharm (Holdings) Plc, Annual General Meeting, Aug 29, 2025 TC Biopharm (Holdings) Plc, Annual General Meeting, Aug 29, 2025. Location: maxim 1, 2 parklands way, holytown, motherwell, united kingdom ml1 4wr, United Kingdom Announcement • Jun 12
TC Biopharm (Holdings) Plc Announces Complete Response in Minimal Residual Disease (MRD) Patient TC BioPharm (Holdings) PLC announced the first patient treated in Cohort B, presenting with detectable Minimal Residual Disease (MRD), is now in complete molecular remission following treatment with the lead drug candidate TCB008. The response was achieved after the patient's second dose of 250,000,000 gamma delta t-cells, two weeks after treatment began, in total the patient received approximately 500,000,000 gamma delta t-cells over two weeks. The patient received 2 of a possible 4 infusions of TCB008 and continues to be monitored under the care of Dr. Hugues de Lavallade at Guy's and St. Thomas' NHS Foundation Trust and remains in remission state two months after treatment. This data readout represents a major milestone in TC BioPharm's mission to develop innovative cell therapies that target and eradicate malignant cells with precision and durability. Over 1 million patients are diagnosed with blood cancers globally each year. Patients who initially achieve remission can retain a molecular burden of disease that results in relapse. Multiple factors, including previous treatments, limit treatment options for relapsed patients. Announcement • May 01
TC Biopharm (Holdings) Plc announced delayed 20-F filing On 04/30/2025, TC Biopharm (Holdings) Plc announced that they will be unable to file their next 20-F by the deadline required by the SEC. Announcement • Mar 19
TC Biopharm (Holdings) Plc Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead TC Biopharm (Holdings) Plc announced initiatives to outsource several functions, moving to a more decentralized model, resulting in reduction in its workforce and creating a leaner and more agile organization as part of the company's strategic developmental plan. The initiatives focus on moving to a CDMO model for production to accommodate larger production demand for future clinical trials, allowing TCB to review alternatives for new manufacturing facilities incorporating newly developed automated and other cell therapy production technologies. Additionally, the company is reviewing alternative approaches for testing and clinical needs, which align with a decentralized drug development model. This approach is expected to result in a workforce reduction of approximately 20 employees, focused largely within the company's production and quality divisions and represents approximately half of the company's total headcount. Separations will be substantially complete by the end of the second quarter 2025 and are expected to reduce the core operational burn rate by approximately 55% compared to 2024.? As a result of these steps, when compared to 2024, the Company estimates partial year 2025 savings to be approximately $2.1 million and annualized savings to be roughly $4.2 million. Announcement • Feb 14
TC BioPharm (Holdings) PLC Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial TC BioPharm (Holdings) PLC announced that it has concluded dosing of Cohort A patients in the ACHIEVE Phase 2B UK clinical trial. The available data show a favorable safety and efficacy response in Cohort A patients, patients with relapse or refractory AML. No patients have experienced any drug-related adverse event, and preliminary efficacy data demonstrate a number of patients attaining stable disease following multiple infusions of TCB008. The ACHIEVE trial is an open-label Phase II study dedicated to evaluating the efficacy and safety of TCB008. This trial is focused on assessing the treatment's effectiveness and tolerability in patients suffering from acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS/AML). Cohort A targeted patients who were ineligible for, or had exhausted all, available therapies, as they were unable to achieve remission or had subsequently relapsed following remission. Cohort A recruitment was re-initiated in July 2024 using higher doses of TCB008 that contained a cumulative dose of up to a billion Gamma Delta T-Cells. Investigator and patient interest in the ACHIEVE trial has allowed the Company to expedite recruitment; as such, enrolment into Cohort A has concluded. Recruitment into Cohort B continues. Announcement • Feb 10
TC BioPharm (Holdings) PLC Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial TC BioPharm (Holdings) PLC announced the first Cohort B patient in the ACHIEVE Phase 2B UK clinical trial, evaluating TCB008 in Acute Myeloid Leukemia, has completed the full dosing regiment. The ACHIEVE trial is an open-label Phase II study dedicated to evaluating the efficacy and safety of TCB008. This trial is focused on assessing the treatment's effectiveness and tolerability on patients suffering from acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS/AML) with challenging cases such as refractory or relapsed conditions. Cohort B recruits patients who have achieved remission following previous treatment yet continue to have a detectable or minimal residual disease (MRD). Recruitment into Cohort B was initiated during the fourth quarter of 2024, ahead of the Company's anticipated schedule. The first Cohort B patient received their dose in October 2024. The initial Cohort B patient has completed the dosing regiment, receiving all four planned doses of TCB008, and is expected to receive an additional fifth dose. Enrolment of a second Cohort B patient has also been initiated. The safety objectives and endpoints of ACHIEVE evaluate patient responses to TCB008, including; grading of adverse events experienced and the incidence and severity of cytokine release syndrome and neurotoxicity. In a review of preliminary data, there are no drug-related adverse events following cumulative infusions of TCB008, containing up to a billion cells. These data continue to support the positive safety profile of TCB008 and the ACHIEVE UK study safety objectives and endpoints. Announcement • Jan 16
TC Biopharm (Holdings) PLC Announces H5N1 Proof of Concept Studies Intention TC Biopharm (Holdings) PLC announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB008, for treatment in H5N1, commonly known as Bird Flu. The Company is currently approaching potential university partners to expedite the preclinical work required for a Phase I study. H5N1 is a viral infection often contracted by contact with sick birds, yet it can also be passed from person to person. Symptoms begin within two to eight days and can seem like the common flu, causing cough, fever, sore throat, muscle aches, headache, and shortness of breath. The disease can carry a high mortality in humans. Some antiviral drugs, if taken within two days of symptoms, may help. Last week, the Louisiana Department of Health recently reported the first U.S. death from H5N1. TCB008 is an allogeneic, unmodified cell therapy made up of activated and expanded gamma delta T (GDT) cells, which the company expects will have applications in treating the emerging avian bird flu epidemic. Due to the highly infectious nature of H5N1, TC BioPharm's goal would be to partner with a leading Infectious Disease Center or University to advance the Proof-of-Concept and pre-clinical studies. Announcement • Dec 20
TC Biopharm (Holdings) Plc Advances ACHIEVE Phase 2b Clinical Trial with Final Dosing of 3 Patients TC Biopharm (Holdings) Plc announced 3 patients have now completed the full-dose regimen in the ACHIEVE Phase 2b trial in the UK with no drug-related Adverse Events seen in any of the restart patients. The ACHIEVE UK clinical trial is an open-label, phase II study designed to evaluate the efficacy and effectiveness of TCB008 in patients with AML or MDS/AML, with either refractory or relapsed disease. To date, 10 patients have received their first dose, 9 patients have received their second dose, 4 patients have received their third dose, and 3 patients have received their fourth and final dose. 9 out of 10 patients recruited to date are in Cohort A, representing relapsed/refractory patients who have been unable to attain remission. One patient has been enrolled into Cohort B, representing patients who have attained remission following prior treatment yet continue to have a detectable residual disease. The patient enrolled in Cohort B received their fourth and final dose in November 2024. Initially, 14 patients are planned to be recruited into Cohort A and Cohort B and, following confirmation of study endpoints, a further 10 patients will be recruited into each cohort, giving a total of 48 patients. The preliminary safety data shows that the 5mL dose of TCB008 is well tolerated, with no drug-related Adverse Events. These data outputs remain aligned with TCB008's safety profile, in support of the ACHIEVE study safety objectives and endpoints. Announcement • Dec 18
TC Biopharm (Holdings) Plc has filed a Follow-on Equity Offering in the amount of $14 million. TC Biopharm (Holdings) Plc has filed a Follow-on Equity Offering in the amount of $14 million.
Security Name: American Depositary Shares
Security Type: Depositary Receipt (Common Stock)
Transaction Features: At the Market Offering Announcement • Oct 26
TC BioPharm Remains Compliant with All Nasdaq Listing Requirements and Continues Trading on the Nasdaq Stock Exchange, Responds to False Social Media Claim TC BioPharm (Holdings) PLC (‘TC BioPharm’ or the ‘Company’) refuted a false claim made earlier this week on social media, stating there is absolutely no way the company is in any danger of being delisted from the Nasdaq stock exchange. The since deleted rumor stated that the company had filed an 8-K Notice to ‘Delist’ from the Nasdaq and would transfer trading to a different exchange. TC BioPharm reiterated that there is no truth to this remark and that TC BioPharm remains in compliance with all Nasdaq listing requirements. The Company will look to take action to defend itself from these types of these attacks which are perpetrated in an effort to create negative market dynamics. Announcement • Sep 03
TC Biopharm (Holdings) Plc Announces Dosing of 5 New Patients in ACHIEVE TC BioPharm (Holdings) PLC announced dosing of 5 new patients in the ACHIEVE Phase 2b trial ongoing in the UK. Currently, the trial has successfully dosed 6 patients with their first of 4 possible doses at the higher dose level. Each 5mL dose contains up to 230 million gamma delta T cells, and a patient is expected to receive up to an approximate 1 billion gamma delta T cells over four doses. Five patients have received their second dose, with 2 of these patients having also received their third dose. This correlates with TCBP's step-wise approach to process improvements, as implemented in Fourth Quarter 2023, and further steps taken to amend the trial protocol in the first quarter of 2024. New patients will continue to be identified, screened, and enrolled into the study. The ACHIEVE UK clinical trial is an open-label, phase II study designed to evaluate the efficacy and effectiveness of TCB008 in patients with AML or MDS/AML, with either refractory or relapsed disease. Announcement • Aug 29
TC BioPharm (Holdings) PLC Announces Grant of European Patent Covering Use of Modified Gamma Delta Cells for the Treatment of Cancer and Viral Indications TC BioPharm (Holdings) PLC announced that it has received a patent grant from European Patent Office (EPO) covering the use of modified gamma delta cells for the treatment of cancer and viral indications. The Company intends to proceed with the patent process in specific European countries in line with the commercial strategy of TCBP. Announcement • Aug 17
TC Biopharm (Holdings) Plc has filed a Follow-on Equity Offering. TC Biopharm (Holdings) Plc has filed a Follow-on Equity Offering.
Security Name: American Depositary Shares
Security Type: Depositary Receipt (Common Stock)
Securities Offered: 1,501,501
Security Name: Pre Funded Warrant
Security Type: Equity Warrant
Securities Offered: 1,501,501
Security Name: Series H Warrants
Security Type: Equity Warrant
Securities Offered: 1,501,501 Announcement • Jul 22
TC BioPharm (Holdings) PLC Announces Dosing of 6th Patient in ACHIEVE Study in Patients with Acute Myeloid Leukemia TC BioPharm (Holdings) PLC announced that on July 16, the sixth patient in ACHIEVE (UK) was treated. This is the first patient treated with a higher dose of TCB-008 post the amendment approved by the MHRA on Feb. 22, 2024. The ACHIEVE UK clinical trial is an open-label, phase II study designed to evaluate the efficacy and effectiveness of TCB-008 in patients with AML or MDS/AML, with either refractory or relapsed disease. ACHIEVE is comprised of two cohorts representing separate disease states. The protocol allows for either cohort to be advanced as an independent Phase III Pivotal Trial upon completion of the cohort, presuming the primary efficacy endpoints is met. Cohort A represents relapsed/refractory patients who have been unable to attain remission and are in palliative care as they are unable to tolerate further chemotherapy. Initially, 5 patients were treated at the lower dose. Up to 14 patients may be recruited into this cohort at the higher dose. Pending confirmation of the primary endpoints, a further 10 patients may be recruited into Cohort A for a total of 24 patients. Cohort B represents patients who have attained remission following prior treatment, however, continue to have a detectable residual disease. Up to 14 patients may be recruited into this cohort at the higher dose. Pending confirmation of the primary endpoints, a further 10 patients may be recruited into Cohort B for a total of 24 patients. Interim data review is not reliant on the completion of either Cohort, and consequently the Company is not required to complete investigation of both Cohorts prior to advancing to a Pivotal Phase 3 study in one or both Cohorts simultaneously. Enrolled patients will be treated with an increased dose of TCB-008, containing up to 230,000,000 cells per dose compared to the previous dose of 35,000,000. The increased dose is commensurate with the proposed medium dose cohort in the Company's FDA trial in AML. Eligible patients will receive up to three additional infusions of TCB008, starting 14 days after the previous infusion and administered every subsequent 14 days, representing a total of 4 doses of TCB-008 or approximately 1,000,000,000 cells. Announcement • Jul 03
TC Biopharm (Holdings) Plc has filed a Follow-on Equity Offering. TC Biopharm (Holdings) Plc has filed a Follow-on Equity Offering.
Security Name: American Depository Shares
Security Type: Depositary Receipt (Common Stock)
Securities Offered: 6,297,230
Security Name: Pre Funded Warrants
Security Type: Equity Warrant
Securities Offered: 6,297,230 Announcement • May 31
TC Biopharm (Holdings) Provides Non-Compliance Update On May 24, 2024, TC Biopharm (Holdings) Plc received written notification from the listing qualifications staff of the Nasdaq Stock Market, LLC (Nasdaq") indicating that the Company was not in compliance with the Minimum Stockholders' Equity Requirement, as of March 31, 2024. This letter indicated that while Nasdaq estimates the Company is currently in compliance with the Minimum Stockholders' Equity Requirement it notes that based on the historical burn rate, without a significant transaction, the Company will not be in compliance as of the next period ending June 30, 2024. Since the Company was previously granted an exception to the Minimum Stockholders Equity Requirement by a Nasdaq Hearings Panel and subsequently regained compliance, it is subject to a Mandatory Panel Monitor in accordance with Nasdaq Listing Rule 5815(d)(4)(A). The Company intends to request a hearing before a hearing panel at which it will request continued listing on The Nasdaq Capital Market since it has returned to compliance and expects to continue to do so. The Company's hearing request will stay the suspension of trading and delisting of the Company's ADSs and Warrants pending the conclusion of the hearing process. Consequently, the Company's ADSs and Warrants will remain listed on The Nasdaq Capital Market at least until the hearing panel renders a decision following the hearing. There can be no assurance that the hearing panel will determine to continue the Company's listing on The Nasdaq Capital Market or that the Company will timely evidence compliance with the terms of any extension that may be granted by the Nasdaq following the hearing. As previously reported in a Current Report on Form 8-K filed with the Securities and Exchange Commission (the SEC") on May 20, 2024 (the May 20 8-K'), on May 15, 2024, TC Biopharm (Holdings) PLC (the Company") filed its Form 10-Q for the quarter ended March 31, 2024 (the Form 10-Q"). As noted in the Form 10-Q, the Company was not in compliance with the minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1) for continued listing on The Nasdaq Capital Market because its stockholders' equity was below the required minimum of $2.5 million (the Minimum Stockholders' Equity Requirement") at March 31, 2024. As previously reported in a Current Report on Form 8-K filed with the SEC on May 8, 2024, on May 6, 2024, the Company entered into a letter agreement (the Inducement Letter") with certain holders (the Holders") of existing Series E warrants (the Existing Warrants") to purchase ordinary shares represented by American depositary shares (the ADSs") of the Company. Pursuant to the Inducement Letter, the Holders agreed to exercise for cash their Existing Warrants to purchase an aggregate of 1,750,000 ADSs of the Company for cash and the payment of 0.099625 (USD 0.125) per new warrant in consideration for the Company's agreement to issue new Series F warrants to purchase ordinary shares represented by ADSs (the New Warrants") to purchase up to 70,000,000 of the Company's ordinary shares represented by 3,500,000 ADSs (the New Warrant ADSs"). On May 8, 2024, the Company received aggregate gross proceeds of approximately 3.1 million (circa $3.9m) from the exercise of the Existing Warrants by the Holders, prior to deducting placement agent fees and estimated offering expenses. As a result, the Company believes that due to the exercise of the Existing Warrants it is now in compliance with the Minimum Stockholders' Equity Requirement. Announcement • May 16
TC Biopharm (Holdings) Plc Announces Launch of Compassionate Use Program for TCB008 TC BioPharm (Holdings) PLC announced that the company's lead therapeutic TCB008 will be available to patients via a newly launched compassionate use program in the UK. Compassionate use refers to the prescription of unlicensed medicinal products to treat a patient in instances where their individual clinical needs cannot be met with the available licensed treatments. Patients enrolling in these clinical trials must meet specific entry criteria, both to protect vulnerable patient populations and ensure the validity of study data. These data must be reviewed and approved by regulatory agencies before products can be marketed as licensed medicinal products for patient treatment. Access to TCB's cell therapy products through the compassionate use program will provide medical practitioners with treatment options for patients who are ineligible to access experimental treatments through ongoing clinical trials. New Risk • Apr 02
New major risk - Revenue size The company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£11m free cash flow). Share price has been highly volatile over the past 3 months (30% average weekly change). Shareholders have been substantially diluted in the past year (over 19x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$1.48m market cap). Announcement • Feb 21
TC Biopharm (Holdings) Plc, Annual General Meeting, Mar 14, 2024 TC Biopharm (Holdings) Plc, Annual General Meeting, Mar 14, 2024, at 09:00 US Eastern Standard Time. Location: Maxim 1, 2 Parklands Way, Holytown, Motherwell ML1WR Motherwell United Kingdom Agenda: To consider in accordance with the quorum requirements of the Nasdaq Marketplace Rules; To consider Without prejudice to any existing authorities, the issuance of securities in one or more non-public offerings be approved in accordance with Nasdaq Marketplace Rule 5635. Announcement • Dec 20
TC Biopharm (Holdings) Plc has filed a Follow-on Equity Offering in the amount of $3.5 million. TC Biopharm (Holdings) Plc has filed a Follow-on Equity Offering in the amount of $3.5 million.
Security Name: American Depository Receipt
Security Type: Depositary Receipt (Common Stock)
Securities Offered: 1,750,000
Price\Range: $2
Transaction Features: Subsequent Direct Listing Announcement • Dec 18
TC BioPharm (Holdings) PLC Appoints Lauren Bor as Head of Commercial Development Division TC BioPharm (Holdings) PLC announced that the creation of a new Commercial Development Division, which will be headed by Dr. Lauren Bor, PhD. Prior to serving as TC BioPharm's Head of Process Development, Dr. Bor completed a Bsc Hons degree in Immunology from the University of Glasgow. She obtained her Ph.D in Immunobiology, titled "The Generation of MHC Class I Restricted Antigen Specific Regulatory T Cells for the treatment of Type 1 Diabetes" from Kings College London in 2014. Dr. Bor then joined the lab of Professor Waseem Qasim at University College London as a Post-Doctoral Researcher where she led the development of closed-system, automated manufacturing platforms for CAR T cells. Following successful manufacture of CD19 CAR T cells for clinical trials and scale up of gene edited CAR T cells at UCL. Lauren Joined TC BioPharm in 2019, and her area of research has been the process development and technology transfer of TC BioPharm's Unmodified cryopreserved V?9Vd2 T cell manufacturing process. Announcement • Nov 29
TC Biopharm (Holdings) Plc Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia TC BioPharm (Holdings) PLC announced that the FDA provides clearance on the Company's investigational new drug (IND) application for a Phase 1B study in relapse/refractory Acute Myeloid Leukemia (AML). The Phase 1B study, dubbed ACHIEVE2, will be a 9 patient, dose escalating study measuring for safety and dose optimization. The Open-label, multi-center study conducted in 2 parts (dose escalation followed by dose expansion) will evaluate safety, persistence/expansion, and preliminary efficacy of single and multiple IV doses of TCB008 in patients with AML or MDS/AML. Patients may be reinfused with TCB008 up to 3 times following initial infusion as deemed appropriate by the investigator or designee should protocol specified criteria be met. Additionally, the Company will be continuing the UK ACHIEVE trial in AML, expecting to submit amendments to the protocol before year-end to align the dosing and other criteria with the ACHIEVE2 trial of TCBP's lead product. New Risk • Aug 04
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£15m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-UK£26k). Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (US$3.84m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£24m net loss next year). Revenue is less than US$5m (UK£3.8m revenue, or US$4.9m). Announcement • Aug 01
TC Biopharm (Holdings) Regains Compliance with the Nasdaq Stock Market Listing Rule 5550(b) TC Biopharm (Holdings) Plc announced that the company has regained compliance with the Nasdaq Stock Market Listing Rule 5550(b) which will maintain the listing of the company's American depositary shares on the Nasdaq Global Select Market. As previously reported on January 19, 2019, the Company received a letter from the listing qualifications staff of the Nasdaq Stock Market, LLC (‘Nasdaq’) indicating that the Company has not regained compliance with the minimum Market Value of Listed Securities (‘MVLS’) of $35,000,000 required for continued listing on The Nasdaq Capital Market or the alternative criteria, as set in Nasdaq Listing Rule 5550(b) (the ‘MVLS Requirement’). Subsequently, the Company submitted to Nasdaq a plan to regain compliance with Nasdaq listing rules. After reviewing the plan of the Company to regain compliance, On July 27, 2023, the company received a letter from Nasdaq notifying the Company that the Panel has concluded the company has regained compliance with the shareholder equity concerns as mentioned previously. The Company will be subject to a Mandatory Panel Monitor for a period of one year from July 27, 2023. Announcement • Jun 09
TC Biopharm (Holdings) Plc, Annual General Meeting, Jun 29, 2023 TC Biopharm (Holdings) Plc, Annual General Meeting, Jun 29, 2023, at 14:00 Coordinated Universal Time. Location: Maxim 1, 2 Parklands Way, Holytown, ML1 4WR Motherwell United Kingdom Agenda: To receive the Company’s annual report and audited financial statements for the year ended 31 December 2022; to receive and approve the Directors’ Remuneration Report for the year ended 31 December 2022, which is set out on pages 21 to 31 of the Company’s Annual Report and Financial Statements for the year ended 31 December 2022; to receive and approve the Directors’ Remuneration Policy; to appoint Ecovis Wingrave Yeats LLP as auditor of the Company, to hold office from the conclusion of this meeting until the conclusion of the next annual general meeting of the Company at which the Company’s financial statements are laid before the Company; and to consider other matters. Reported Earnings • May 04
Full year 2022 earnings: EPS and revenues exceed analyst expectations Full year 2022 results: UK£2.02 loss per share (improved from UK£6.49 loss in FY 2021). Revenue: UK£3.84m (up 94% from FY 2021). Net loss: UK£1.39m (loss narrowed 90% from FY 2021). Revenue exceeded analyst estimates by 94%. Earnings per share (EPS) also surpassed analyst estimates by 83%. Announcement • Feb 15
TC Biopharm Appoints Arlene Morris as New Chair of the Board TC Biopharm (Holdings) PLC announced the appointment of Arlene M. Morris to the position of Chair of the Board. Ms. Morris has held a seat on the TC BioPharm board as an independent director since 2022. An accomplished biotech executive and board member, with many years of experience, Ms. Morris has a proven track record of evolving businesses and enhancing their outcomes through deep knowledge and guidance. Her leadership in business development and strategic marketing offer unique oversight to the company as TC BioPharm advances through clinical trials. She has been instrumental in high-profile corporate partnering sell side deals worth hundreds of millions of dollars and been instrumental in reverse mergers including Albireo (Biodel), Viridian (MiRagen) and Cogent (Unum). Additionally, she has coordinated financings for private and public companies in excess of $250 million. Ms. Morris is the CEO of Willow Advisors LLC a biotech advisory firm. She was previously the CEO and president of Syndax Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of an epigenetic therapy for treatment-resistant cancers and Affymax focused on the development of peptide therapeutics. She also serves as a board of directors member of the U.S.-based biotech companies Palatin Technologies Inc., Cogent Therapeutics Inc., and Viridian Therapeutics Inc. Ms. Morris is also on the Board of Viveve a publicly traded medical device company. She is on the Board of the Charleston Animal Society. She was formerly on the board of the Foundation for Research Development of the Medical University of South Carolina and Carlow University and previously served on numerous other public company boards including most recently the Dimension, Biodel and Neovacs SA Boards as well as the Board of BIO and the Humane Society of Silicon Valley.Ms. Morris received a B.A. in Biology from Carlow College. Announcement • Feb 08
TC Biopharm (Holdings) Plc Announces Successful Dosing of Final Patient in ACHIEVE Safety Cohort TC Biopharm (Holdings) Plc announced the official dosing of its final patient from the safety cohort for ACHIEVE, its phase 2B clinical trial of OmnImmune® (TCB008) for treatment of Acute Myeloid Leukemia (AML). TC BioPharm's trial involved administering TCB008, the Company's novel drug to treat AML, to pathologically confirmed diagnosed patients afflicted with this type of cancer. The initial 5 patients of the trial were spaced two weeks apart with safety review by an oversight board. This safety cohort is in line with TCBP's stepwise clinical trial advancement, moving from donor matching in the Phase 1b to a universal donor model with no HLA matching of donor to patient. Pending the final review of the Data Safety Monitoring Board (DSMB), the Company will move to open enrolment of the trial, and expect a positive formal review from the DSMB in February. Announcement • Jan 31
TC BioPharm (Holdings) plc Announces the Appointment of Bree Harlin as Chief Clinical Officer TC BioPharm (Holdings) PLC announced the appointment of Bree Harlin as Chief Clinical Officer (CCO), effective immediately. Ms. Harlin brings more than twenty years of experience in research, oncology and clinical stage drug development to TC BioPharm. Most recently she was with Loxo at Lilly, where she worked on the clinical development of targeted therapies for various types of solid and hematologic cancers. She has worked in clinical development and operations across multiple therapeutic areas at large pharma and small biotech companies for the majority of her career which began in academia working on clinical trials at Mass General and Brigham and Women's Hospital. She will be based in New York, NY. Announcement • Jan 20
TC Biopharm Receives Notice of Non-compliance with NASDAQ's Listing Rule 5550(b)(1) TC Biopharm (Holdings) PLC has received written notification from the listing qualifications staff of the Nasdaq Stock Market, LLC ("Nasdaq") indicating that the Company has not regained compliance with the minimum Market Value of Listed Securities ("MVLS") of $35,000,000 required for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(b)(2) (the "MVLS Requirement"). The Company intends to request a hearing which will stay the suspension or delisting action pending the hearing and the expiration of any extension period granted by the Panel following the hearing. TC Biopharm intends to present the Nasdaq panel with a comprehensive plan to address the current deficiency in relation to the market value of the Company's listed securities to maintain the Nasdaq listing. Consequently, the Company's ADSs and Warrants will remain listed on The Nasdaq Capital Market at least until the Panel renders a decision following the hearing management is confident in its plan of compliance and the business model. The Notification has no immediate effect on the listing of the shares, and the stock will continue to trade on the Nasdaq Capital Market. As previously reported, on July 15, 2022, the Company received written notice from Nasdaq indicating that the Company was no longer in compliance with the MVLS Requirement. In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company had a period of 180 calendar days, or until January 11, 2023, to regain compliance with the MVLS Requirement. Reported Earnings • Dec 13
First half 2022 earnings released: EPS: UK£0.93 (vs UK£6.78 loss in 1H 2021) First half 2022 results: EPS: UK£0.93 (up from UK£6.78 loss in 1H 2021). Revenue: UK£989.3k (flat on 1H 2021). Net income: UK£512.7k (up UK£3.16m from 1H 2021). Profit margin: 52% (up from net loss in 1H 2021). Board Change • Nov 16
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 2 experienced directors. 1 highly experienced director. Co-Founder & Executive Chairman of the Board Michael Leek is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Jul 29
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 2 experienced directors. 1 highly experienced director. Co-Founder & Executive Chairman of the Board Michael Leek is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Mar 30
High number of new directors Non-Executive Independent Director Arlene Morris was the last director to join the board, commencing their role in 2022. Announcement • Feb 24
TC Biopharm (Holdings) Plc Announces Appointment of New Board Members TC Biopharm (Holdings) Plc announced the appointment of 4 new members to its Board of Directors. Joining the board are Mark Bonyhadi, James Culverwell, Arlene Morris and Edward Niemczyk. The new additions became effective upon completion of company's recent IPO. These appointments bring the company's total board membership to 7. Mark Bonyhadi, PhD is a Senior Advisor at Qiming Venture Partners USA. Prior to joining Qiming, he held positions of Vice President of Research, Head of Academic Affairs, and Vice President of Process Research Sciences at Juno Therapeutics. James Culverwell is currently Chairman of HOX Therapeutics. Previously, he has served as a director and chairman of the audit committee of Innocoll Holdings plc. Addiitonally, James has served as a non-executive director and chairman of the audit committee at Amryt Pharmaceuticals plc. Arlene Morris currently serves as a non-executive director of the following companies: Cogent Biosciences Inc., Viridian Therapeutics Inc. and Palatin Technologies Inc. Ms. Morris has also served as a non-executive director at Neovacs SA, Dimension Therapeutics, Biodel Inc., and MediciNova Inc. Ed Niemczyk is a Partner at Bridges Fund Management Ltd. He has been with Bridges' U.S. Sustainable Growth Fund since 2016 and leads its healthcare efforts in the U.S. Whilst at Bridges he served on the board of directors of the following private companies, which are, or have been, investees of Bridges: Impact Fitness North America, LP, Medwood Services, LLC (chairman of the board); Sunrise Treatment Center, LLC (chairman of the board) Jump City Holdings Inc., James River Home Health and Hospice, LLC and Altius Healthcare Management, LLC (chairman of the board). Announcement • Feb 11
TC Biopharm (Holdings) Plc has completed an IPO in the amount of $17.54118 million. TC Biopharm (Holdings) Plc has completed an IPO in the amount of $17.54118 million.
Security Name: American Depositary Shares
Security Type: Depositary Receipt (Common Stock)
Securities Offered: 4,117,648
Price\Range: $4.24
Discount Per Security: $0.3392
Security Name: Warrants
Security Type: Equity Warrant
Securities Offered: 8,235,296
Price\Range: $0.01
Discount Per Security: $0.0008 Board Change • Feb 08
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). CFO & Director Martin Thorp was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. 
